Enhanced Lysosomal Exocytosis Drives Cartilage Pathology in MPS IVA Models

Study Background and Research Question

Lysosomes are central to maintaining cellular homeostasis, acting as hubs for macromolecule degradation, membrane trafficking, and signaling. Dysregulation of these processes underlies a spectrum of rare inherited diseases collectively known as lysosomal storage disorders (LSDs). Among these, mucopolysaccharidosis type IVA (MPS IVA)—or Morquio A syndrome—presents with pronounced skeletal abnormalities, yet the precise cellular mechanisms driving this pathology remain incompletely understood. While the traditional view emphasizes the role of storage material accumulation, recent evidence suggests that downstream pathways, such as abnormal growth factor signaling and altered lysosomal exocytosis, may play equally critical roles in disease onset and progression. The reference study (Disease Models & Mechanisms, 2026) specifically asks: does enhanced lysosomal exocytosis, independent of substrate storage, contribute to cartilage pathology in MPS IVA?

Key Innovation from the Reference Study

The central innovation of this work lies in establishing a mechanistic link between increased lysosomal exocytosis and disrupted growth factor signaling during cartilage development in an in vivo zebrafish model of MPS IVA. While previous research has linked lysosomal dysfunction to skeletal pathology, this study provides direct evidence that enhanced exocytosis—a process by which lysosomes fuse with the plasma membrane to release their contents—can itself become pathogenic. By disentangling the effects of substrate accumulation from those of exocytosis-driven protease mislocalization, the authors challenge prevailing paradigms and refine our understanding of LSD pathogenesis.

Methods and Experimental Design Insights

The researchers used zebrafish genetically deficient in N-acetyl galactosamine-6-sulfatase (galns), the enzyme mutated in MPS IVA, to model disease progression. Key experimental approaches included:

• Live imaging of lysosomal dynamics: Fluorescent probes and confocal microscopy tracked lysosomal movement and exocytosis events in developing cartilage.
• Biochemical assays for lysosomal enzyme release: Lysosomal β-hexosaminidase release assays quantified exocytosis activity, leveraging well-established protocols for measuring enzyme secretion from live cells.
• Immunohistochemistry and protease activity assays: The presence and activity of cathepsins and key signaling proteins (e.g., TGFβ, BMP pathway members) were assessed in both intracellular and extracellular compartments.
• Comparative analyses with sialidosis and MLII models: To contextualize findings, results were compared to related LSD models where exocytosis and enzyme mislocalization are implicated.

This multi-layered methodological approach enabled the authors to map both the spatial and functional consequences of lysosomal exocytosis dysregulation during cartilage development.

Core Findings and Why They Matter

The study’s principal findings reshape our view of MPS IVA pathogenesis:

• Enhanced lysosomal exocytosis in galns-deficient cartilage: Mutant zebrafish displayed a significant increase in lysosome-plasma membrane fusion events, as visualized by live imaging and corroborated by elevated extracellular β-hexosaminidase activity.
• Altered protease localization and activity: Contrary to models like sialidosis, where exocytosis leads to increased extracellular cathepsin activity, MPS IVA mutants showed reduced cathepsin activity outside cells. This suggests a nuanced, context-dependent outcome of lysosomal exocytosis perturbation.
• Disrupted growth factor signaling: Decreased levels of TGFβ and BMP signaling components were observed, implicating protease-mediated degradation or altered glycosaminoglycan environments as mechanisms for impaired skeletal development.
• Shifts in glycosaminoglycan abundance: Both intracellular and extracellular pools of these macromolecules were altered, supporting the hypothesis that exocytosis affects not just enzymes but also matrix components crucial for cartilage integrity.

Together, these results indicate that lysosomal exocytosis, beyond storage accumulation, is a key driver of cartilage pathology in MPS IVA. This expands therapeutic and experimental focus from substrate reduction alone to include the regulation of exocytosis and protease trafficking.

Comparison with Existing Internal Articles

Several recent reviews and experimental reports align with and extend the findings of this study. For example, the article "Enhanced Lysosomal Exocytosis Drives Cartilage Pathology in MPS IVA" underscores the pathogenic potential of exocytosis-driven protease mislocalization in LSD models, while "Decoding Lysosomal Exocytosis: Strategic Pathways and Pre..." explores translational strategies for targeting Ca2+-dependent lysosomal exocytosis in disease contexts. These internal resources collectively highlight the growing recognition of lysosome-mediated membrane trafficking as a central node in both basic cell biology and disease modeling. The reference study builds on these insights by providing in vivo functional data linking exocytosis to specific developmental outcomes in cartilage.

Limitations and Transferability

Despite its strengths, the study has several limitations. The use of zebrafish, while offering powerful developmental and imaging advantages, may not fully recapitulate human cartilage physiology or the complexity of MPS IVA in patients. Moreover, the observed context-specific differences in cathepsin activity between disease models caution against assuming a universal role for exocytosis across all LSDs. The mechanistic interplay between exocytosis, extracellular protease activity, and growth factor signaling remains complex and may involve additional, as yet unidentified, regulatory circuits. Transferability to mammalian models and clinical contexts will require further validation.

Protocol Parameters

• Lysosomal β-hexosaminidase release assay: Prepare live cartilage tissue or cultured cells from zebrafish or mammalian models; collect extracellular media after stimulation (e.g., Ca2+ ionophore) and quantify β-hexosaminidase activity using chromogenic or fluorogenic substrates.
• Inhibition of lysosomal exocytosis: Experimental protocols commonly use 1–10 μM concentrations of a lysosomal exocytosis inhibitor (such as Vacuolin-1) for 1–4 hours in cultured cells to block Ca2+-dependent lysosome-plasma membrane fusion. Parameters may need optimization depending on the cell type and desired readout.
• Growth factor signaling assessment: Immunostaining or western blotting for TGFβ/BMP pathway markers can be performed on both tissue sections and conditioned media to assess changes in signaling output due to exocytosis disruption.

Research Support Resources

Researchers aiming to interrogate the mechanisms revealed by this study can benefit from specific chemical tools. Vacuolin-1 (SKU C4084) is a well-characterized, cell-permeable lysosomal exocytosis inhibitor validated for use in lysosomal β-hexosaminidase release assays and membrane repair research. As detailed in APExBIO's product information, Vacuolin-1 provides selective inhibition of Ca2+-dependent lysosome-plasma membrane fusion, enabling precise dissection of exocytosis-dependent signaling pathways in cell biology and disease models. For detailed workflow recommendations and troubleshooting strategies, see the guide "Vacuolin-1: Precision Lysosomal Exocytosis Inhibitor Workflows."